Daniel Griffin provides a clinical update on COVID-19, then Sabra Klein joins us to discuss the effect of sex, gender, and age on viral infectious disease, including COVID-19. Click arrow to playDownload TWiV 624 (74 MB .mp3, 123 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Peter Daszak joins TWiV to explain the work of EcoHealth Alliance in surveillance of bats in China for SARS-related coronaviruses to provide the information needed to prevent future pandemics, and why NIH recently withdrew financial support for their work. Click arrow to playDownload TWiV 623 (41 MB .mp3, 68 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …
TWiV 623: Bats and coronaviruses with Peter Daszak Read More »
Emmie de Wit joins TWiV to explain her work on the pathogenesis of infection with SARS-CoV-2 in rhesus macaques, including studies on remdesivir and a vaccine candidate. Click arrow to playDownload TWiV 622 (41 MB .mp3, 68 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Daniel Griffin provides a clinical update on COVID-19, then we review an Ad5 vectored SARS-CoV-2 vaccine, reports on remdesivir and hydroxychloroquine, a drug repurposing study, why some patients infect many others, reducing viral transmission, and much more, including listener email. Click arrow to playDownload TWiV 621 (91 MB .mp3, 152 min)Subscribe (free): iTunes, Google Podcasts, RSS, emailBecome a patron of TWiV! Show notes …
Jon Yewdell returns to explain studies on detection of antibodies and T cell epitopes in patients who have recovered from COVID-19. Click arrow to playDownload TWiV 620 (67 MB .mp3, 111 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Small animal models (mice, ferrets, hamsters) are essential for understanding how SARS-CoV-2 causes disease and for pre-clinical evaluation of vaccines and antiviral therapeutics. One promising model has been developed by modifying SARS-CoV-2 so that it binds to murine ACE2. Laboratory mice cannot be infected with SARS-CoV-2 because the viral spike glycoprotein (illustrated) does not bind …
